Aeluma is now a CHIPS Act option masquerading as a defense-photonic micro-cap. The third fiscal quarter, ended March 31, 2026, printed $1.222 million in revenue, down 2.6% from the year-ago quarter's $1.255 million, against a loss from operations of $2.125 million and a GAAP net loss of $1.800 million, or $0.10 per share. The sequential and year-over-year story is small; the balance-sheet story is large. Cash and equivalents ended the quarter at $37.78 million, up from $3.628 million at the prior fiscal year-end, lifted by a $25.4 million gross underwritten offering in September 2025 and a $13.8 million gross offering in March 2025, and the company filed a new $50 million at-the-market sales agreement in March 2026. Then on July 29, 2026, Aeluma disclosed a CHIPS and Science Act letter of intent for up to $30 million, with an explicit government-stake-on-issuance clause that converts a portion of the award into equity at award time. The thesis is that Aeluma's scalable, non-InP, large-diameter substrate platform solves a real supply-chain problem for AI optical interconnects, and the federal government has now put its balance sheet behind that thesis.
The single load-bearing risk is concentration. Two customers generated 76% of accounts receivable at March 31, 2026, and the nine-month revenue mix shows 68% and 15% from the top two customers, with 60% and 16% in the latest quarter. The path to commercial scale runs through a small number of government and consumer-electronics counterparties, and a delay or pivot at any one of them would compress the thesis. The falsifiable clock is the next two data points: the company's next 10-K (for the fiscal year ending June 30, 2026) should land in September and disclose the actual revenue mix and burn trajectory under the new commercial-revenue framing, and the conversion of the July 29 letter of intent into definitive CHIPS award documents will determine whether the $30 million becomes a real cash flow or a press-release overhang.